At a press conference held by the State Council on March 17, Wang Junzhi, an academician of the Chinese Academy of Engineering, pointed out that most of the pre-clinical studies (including animal efficacy and safety studies) have been completed for the first nine novel coronavirus vaccines. Most of the scientific teams will complete preclinical studies by April and gradually start clinical trials.

(information from CNR News:  http://china.cnr.cn/news/20200318/t20200318_525020320.shtml)

According to CanSino Biologics Inc. (March 17), the restructuring coronavirus vaccine (adenovirus vector), developed by CanSino Biologics and Biological Engineering Research Institute of Academy of Military Medical Sciences united team, has been approved to start the phase I clinical trial in Wuhan recently. The Vaccine become China’s first novel coronavirus vaccine candidates entered the clinical trials.

As the most experienced platform for drug non-clinical assessment in China, JOINN has rapidly organized a strong expert team to develop scientific and rigorous non-clinical evaluation programs for different types of anti-COVID-19 vaccines/drugs, since the outbreak of the epidemic. At the same time, the company opened a green channel for the anti-coronet project, prepared sufficient experimental materials, including experimental animals, and tried to start the non-clinical assessment work in the shortest time. JOINN has also established clinical bioassay and testing capabilities in Wuhan and other severely affected areas to support the development of human clinical trials, accelerating the research and development process of drug candidates against COVID-19, so as to fight the epidemic and save lives. Up to now, JOINN has undertaken the evaluation of dozens of new coronavirus vaccines, including DNA vaccines, mRNA vaccines, inactivated viral vaccines, recombinant protein vaccines, polypeptide vaccines, and other viral vector vaccines. Most of these projects have started or completed animal experiments, and some have been submitted for clinical approval. In addition, the company is also participant in the safety assessment and clinical trials of several anti-coronavirus antibodies, stem cells, and small molecule drugs.